The Fund's investment objective is to provide an above average yield together with capital growth by investing predominantly in the UK.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 6.7% |
Vodafone Group | 5.7% |
Royal Dutch Shell B | 5.3% |
British American Tobacco | 4.9% |
BP | 4.3% |
AstraZeneca | 3.6% |
Imperial Tobacco Group | 3.3% |
Unilever | 3.1% |
Aberforth UK Small Companies | 2.5% |
Reckitt Benckiser Group | 2.4% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 6.7% |
Vodafone Group | 5.7% |
Royal Dutch Shell B | 5.3% |
British American Tobacco | 4.9% |
Other | 77.4% |
Date | 13-Nov-2024 |
---|---|
NAV | 302.20p |
Currency | GBP |
Change | -2.30p |
% | -0.76% |
YTD change | 4.80p |
YTD % | 1.61% |
Fund Inception | 16/07/1975 |
---|---|
Fund Manager | HSBC Multimanager |
TER | 1.65 (15-Jan-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £500 |
Savings | £50 |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.06 |
You are here: research